




RealRate

PHARMACEUTICAL 2019

Alnylam Pharmaceuticals INC
Rank 114 of 361

Alnylam@20



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Alnylam Pharmaceuticals INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 69% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	1,200,696
Cost of Goods Sold	1,802
Intangible Assets	0
Liabilities, Current	179,494
Liabilities, Non-Current	5,423
Other Assets	53,448
Other Compr. Net Income	1,220
Other Expenses	823
Other Liabilities	87,920
Other Net Income	53,999
Other Revenues	74,908
Property and Equipment	320,658
Research and Development	505,420
Selling, General and Administrative Expense	382,359

Output Variable	Value in 1000 USD
Assets	1,574,802
Liabilities	272,837
Expenses	890,404
Revenues	74,908
Stockholders Equity	1,301,965
Net Income	-761,497
Comprehensive Net Income	-760,887
BaseVar	1,434,085
ECR before Limited Liability	225%
Economic Capital Ratio	319%